Since our last update in November 2024, the ENDEAVOR Project has made significant strides toward achieving its mission: to improve patient outcomes and reduce healthcare costs through precision-driven, patient-centered innovation.
About ENDEAVOR
Funded by the European Union’s Horizon Europe program, ENDEAVOR aims to develop a cost-effective, biomarker-based method to identify patients with Barrett’s Esophagus who are at higher risk of developing esophageal adenocarcinoma, a severe subtype of esophageal cancer. By enabling early and accurate risk detection, this method will support clinicians in selecting the most appropriate treatment and surveillance strategies for each individual — a truly personalized approach to care.
Collaboration Across Europe
A hallmark of ENDEAVOR’s progress has been its widespread international collaboration. The consortium brings together 14 academic institutions, 3 general hospitals, and 2 industrial partners across 9 EU countries, engaging specialists from multiple disciplines including gastroenterology, oncology, pathology, social science and data science.
This diverse expertise ensures that ENDEAVOR’s findings reflect the complexity of real-world clinical practice and that its solutions are practical, scalable, and sustainable.
Highlights from the Past Year
In April 2025, partners gathered in Ireland for the Annual Consortium Meeting, a milestone event that reviewed progress, aligned strategies, and set the roadmap for the next phase of implementation. ENDEAVOR partners also showcased project insights at several major scientific gatherings, including the European Society for Diseases of the Esophagus, the Belgian Association of Cancer Research and the Belgian Week of Gastroenterology, where discussions focused on improving patient quality of life, refining risk-based surveillance programs and presenting a novel brush sampling technique.
A key development has been the continued engagement of the Public and Patient Involvement (PPI) Panel, ensuring that patient perspectives remain central to ENDEAVOR’s design and decision-making processes.
Expected Impact
ENDEAVOR’s biomarker-driven approach is designed to:
-
Increase quality of life for patients by reducing unnecessary procedures and focusing surveillance where it is most needed.
-
Support clinicians in making better-informed, evidence-based decisions about patient care.
-
Reduce healthcare costs by improving efficiency and targeting resources effectively.
Ultimately, the project seeks to enable more efficient and cost-effective surveillance for patients with Barrett’s Esophagus and early cancers who undergo endoscopic treatment. This patient-tailored model will not only enhance outcomes but also increase caregiver satisfaction and confidence in the care process.
Next Steps
Looking ahead, the consortium will use the insights gained so far to refine the risk-stratification method, with the goal of further validating its accuracy and applicability. The lessons learned through ENDEAVOR may also open pathways to extend this biomarker-based approach to other cancer types, amplifying its potential impact across healthcare systems.
Join the Journey
ENDEAVOR continues to move from inspiration to implementation, guided by a shared commitment to innovation, collaboration, and patient benefit. Stay connected with the project’s progress and upcoming milestones by visiting ENDEAVOR’s blog or following them on social media.
https://x.com/EndeavorEU
https://www.linkedin.com/company/endeavor-eu
.png){kind=logo}
